^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    precemtabart tocentecan (M9140)

    i
    Other names: M9140, M-9140, M 9140
    Associations

    News

    Trials
    Company:
    EMD Serono
    Drug class:
    Topoisomerase I inhibitor, CEACAM5-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    20d
    Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (clinicaltrials.gov)
    P1/2, N=250, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
    New P1/2 trial • Pan tumor • Metastases
    |
    precemtabart tocentecan (M9140)
    9ms
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: May 2025 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • capecitabine • precemtabart tocentecan (M9140)
    10ms
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, EMD Serono Research & Development Institute, Inc. | N=31 --> 180 | Trial completion date: Nov 2023 --> May 2025 | Trial primary completion date: Nov 2023 --> Apr 2024
    Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • capecitabine • precemtabart tocentecan (M9140)
    over2years
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, EMD Serono Research & Development Institute, Inc.
    New P1 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    precemtabart tocentecan (M9140)